Petschner et al. [48] provide additional clinical context, demonstrating that MO patients exhibit downregulated retinoic acid signaling (via CYP26B1) and immune-metabolic pathways in blood transcriptomics, which may explain the comorbidity between MO and gastrointestinal disorders. The gene discussed is CYP26B1; the disease is digestive system disorder.